Atezolizumab monotherapy was effective in the cervical cancer cohort. The interim benefit threshold was crossed in patients with follicular/papillary thyroid cancer, thymoma, and GEP and lung NETs, but recruitment was stopped before these signals could be confirmed in stage II. Safety was consistent with previous findings.
Jeffrey R. Infante, Aaron R. Hansen, Michael J. Pishvaian, Laura Q.M. Chow, Grant A. McArthur, Todd M. Bauer, Stephen V. Liu, Shahneen Sandhu, Frank Tsai, Jeong Kim, Eric Stefanich, Chi‐Chung Li, Houston Gilbert, Bruce McCall, Maria Anderson, Mahrukh Huseni, Ina Rhee, Lillian L. Siu, Michael S. Gordon
Jean‐Luc Van Laethem, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Abby B. Siegel, Michael Chisamore, Anran Wang, Andrew X. Zhu
Shahneen Sandhu, Victoria Atkinson, María González Cao, Theresa Medina, Ainara Soria Rivas, Alexander M. Menzies, Ivor Caro, Louise Roberts, Yuyao Song, Yibing Yan, Guo Yu, Cloris Xue, Georgina V. Long
Ivan Borbath, Jean‐Luc Van Laethem, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Francesca Bergamo, Per Stål, Debashis Sarker, Daniel H. Palmer, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Abby B. Siegel, Ken Hatogai, Anran Wang, Arndt Vogel
Discussion(0)
No comments yet. Be the first to comment.